Electroconvulsive therapy (ECT) is effective in the treatment of depression. Delayed post-ECT delirium is rare but can occur in a small subset of patients with risk factors and in most cases resolves with the use of psychotropic medications. We report a unique presentation of a patient who developed a delayed post-ECT delirium with fecal incontinence that commenced 24 hours after the administration of ECT. The condition resolved spontaneously after 48 hours without the use of psychotropic medications. 1. Introduction ECT is an important treatment for severe depression including medication refractory depressive symptoms, mania, schizophrenia, and catatonia [1]. However, in the United States, ECT is most commonly used for the treatment of unipolar depression after multiple trials of psychotropic medications have failed to achieve either an adequate response or remission [2]. Although the exact mechanism of action is unknown, a variety of theories postulate that ECT increases monoamine neurotransmitter availability, induces a release of hypothalamic or pituitary hormones, and increases neurogenesis or synaptogenesis [3–5]. ECT has also been shown to have anticonvulsant properties [6]. Cardiovascular complications are the most common causes of morbidity and mortality following ECT [7, 8]. Other complications include headaches, muscle pain, fatigue, and nausea [9, 10]. Anterograde and retrograde amnesia are common ECT-related cognitive complaints [8]. Typically, anterograde amnesia resolves within a few weeks whereas retrograde amnesia is more persistent [8]. Both types of amnesia are more common with bilateral stimulation, high-intensity electrical dosage, and sinus waveform stimulus [11–13]. Mild confusion is reported in about 40% of cases; however, delirium is common following the first seizure or in those with predisposing brain pathology such as white matter lesions [9, 14, 15]. Additionally, patients taking lithium or dopaminergic medications concurrently with ECT are at an increased risk of delirium [16]. We present the case of a highly functional 41-year-old Caucasian woman who developed a severe and prolonged ECT-related delirium. 2. Case Presentation Ms. XX, a 41-year-old Caucasian woman with no known medical illnesses was diagnosed with unipolar major depressive disorder at the age of 27 years. The current episode was her 3rd, lasted over 4 months, and had only partially responded to psychotropic medications including the combination of lithium carbonate 300？mg twice a day, mirtazapine 15？mg daily, and venlafaxine XR 450？mg daily. Ms. XX had also
References
[1]
S. H. Lisanby, “Electroconvulsive therapy for depression,” The New England Journal of Medicine, vol. 357, no. 19, pp. 1939–1945, 2007.
[2]
C. H. Kellner, R. M. Greenberg, J. W. Murrough, E. O. Bryson, M. C. Briggs, and R. M. Pasculli, “ECT in treatment-resistant depression,” The American Journal of Psychiatry, vol. 169, no. 12, pp. 1238–1244, 2012.
[3]
G. R. Heninger, P. L. Delgado, and D. S. Charney, “The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans,” Pharmacopsychiatry, vol. 29, no. 1, pp. 2–11, 1996.
[4]
R. Kamil and R. T. Joffe, “Neuroendocrine testing in electroconvulsive therapy,” Psychiatric Clinics of North America, vol. 14, no. 4, pp. 961–970, 1991.
[5]
F. Chen, T. M. Madsen, G. Wegener, and J. R. Nyengaard, “Repeated electroconvulsive seizures increase the total number of synapses in adult male rat hippocampus,” European Neuropsychopharmacology, vol. 19, no. 5, pp. 329–338, 2009.
[6]
H. A. Sackeim, “The anticonvulsant hypothesis of the mechanisms of action of ECT: current status,” The Journal of ECT, vol. 15, no. 1, pp. 5–26, 1999.
[7]
C. A. Welch and L. J. Drop, “Cardiovascular effects of ECT,” Convulsive Therapy, vol. 5, no. 1, pp. 35–43, 1989.
[8]
C. J. Datto, “Side effects of electroconvulsive therapy,” Depress Anxiety, vol. 12, no. 3, pp. 130–134, 2000.
[9]
H. A. Sackeim, F. R. Ross, and N. Hopkins, “Subjective side effects acutely following ECT: associations with treatment modality and clinical response,” Convulsive Therapy, vol. 3, no. 2, pp. 100–110, 1987.
[10]
C. Datto, J. Kastenberg, D. Miller, D. Knight, and M. P. Szuba, “Prophylactic measures for ECT-induced migraine headaches. Abstracts from the Association for Convulsive Therapy Annual Meeting,” The Journal of ECT, vol. 14, no. 2, p. 135, 1998.
[11]
H. A. Sackeim, J. Prudic, D. P. Devanand et al., “Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy,” The New England Journal of Medicine, vol. 328, no. 12, pp. 839–846, 1993.
[12]
B. Lerer, B. Shapira, A. Calev et al., “Antidepressant and cognitive effects of twice- versus three-times-weekly ECT,” American Journal of Psychiatry, vol. 152, no. 4, pp. 564–570, 1995.
[13]
C. H. Kellner, R. R. Monroe Jr., J. Pritchett, M. P. Jarrell, H. J. Bernstein, and C. M. Burns, “Weekly ECT in geriatric depression,” Convulsive Therapy, vol. 8, no. 4, pp. 245–252, 1992.
[14]
C. E. Coffey, G. S. Figiel, W. T. Djang, M. Cress, W. B. Saunders, and R. D. Weiner, “Leukoencephalopathy in elderly depressed patients referred for ECT,” Biological Psychiatry, vol. 24, no. 2, pp. 143–161, 1988.
[15]
C. E. Coffey, “Brain morphology in primary mood disorders: implications for electroconvulsive therapy,” Psychiatric Annals, vol. 26, no. 11, pp. 713–716, 1996.
[16]
M. Fink, “Post-ECT delirium,” Convulsive Therapy, vol. 9, no. 4, pp. 326–330, 1993.
[17]
A. Chopra and C. L. Sola, “A case of prolonged interictal ECT-induced delirium,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 22, no. 2, pp. E32–E33, 2010.
[18]
A. G. Selvaraj and S. K. Praharaj, “Delayed onset and prolonged interictal delirium following electroconvulsive therapy,” Psychogeriatrics, vol. 12, no. 3, pp. 211–213, 2012.
[19]
W. F. Daniel, R. D. Weiner, and H. F. Crovitz, “ECT-induced delirium and further ECT: a case report,” American Journal of Psychiatry, vol. 140, no. 7, pp. 922–924, 1983.
[20]
A. F. Schatzberg, Essentials of Clinical Pharmacology, American Psychiatric Press, Washington, DC, USA, 2006.
[21]
G. S. Figiel, C. E. Coffey, W. T. Djang, G. Hoffman Jr., and P. M. Doraisw amy, “Brain magnetic resonance imaging findings in ECT-induced delirium,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 2, no. 1, pp. 53–58, 1990.
[22]
W. J. Burke, E. H. Rubin, C. F. Zorumski, and R. D. Wetzel, “The safety of ECT in geriatric psychiatry,” Journal of the American Geriatrics Society, vol. 35, no. 6, pp. 516–521, 1987.
[23]
M. Martin, G. Figiel, G. Mattingly, C. F. Zorumski, and M. R. Jarvis, “ECT-induced interictal delirium in patients with a history of a CVA,” Journal of Geriatric Psychiatry and Neurology, vol. 5, no. 3, pp. 149–155, 1992.
[24]
D. P. Devanand, K. M. Briscoe, and H. A. Sackeim, “Clinical features and predictors of postictal excitement,” Convulsive Therapy, vol. 5, no. 2, pp. 140–146, 1989.
[25]
J. G. Small and V. Milstein, “Lithium interactions: lithium and electroconvulsive therapy,” Journal of Clinical Psychopharmacology, vol. 10, no. 5, pp. 346–350, 1990.
[26]
J. F. Penney, S. H. Dinwiddie, C. F. Zorumski, and R. D. Wetzel, “Concurrent and close temporal administration of lithium and ECT,” Convulsive Therapy, vol. 6, no. 2, pp. 139–145, 1990.
[27]
A. Coppen, M. T. Abou-Saleh, and P. Milln, “Lithium continuation therapy following electroconvulsive therapy,” British Journal of Psychiatry, vol. 139, no. 4, pp. 284–287, 1981.
[28]
R. A. Remick, “Acute brain syndrome associated with ECT and lithium,” Canadian Psychiatric Association Journal, vol. 23, no. 2, pp. 129–130, 1978.
[29]
M. R. Mandel, J. Madsen, A. L. Miller, and R. J. Baldessarini, “Intoxication associated with lithium and ECT,” American Journal of Psychiatry, vol. 137, no. 9, pp. 1107–1109, 1980.
[30]
S. K. Ahmed and G. S. Stein, “Negative interaction between lithium and ECT,” British Journal of Psychiatry, vol. 151, pp. 419–420, 1987.
[31]
R. D. Weiner, A. D. Whanger, W. Erwin, and W. P. Wilson, “Prolonged confusional state and EEG seizure activity following concurrent ECT and lithium use,” American Journal of Psychiatry, vol. 137, no. 11, pp. 1452–1453, 1980.
[32]
R. S. El-Mallakh, “Complications of concurrent lithium and electroconvulsive therapy: a review of clinical material and theoretical considerations,” Biological Psychiatry, vol. 23, no. 6, pp. 595–601, 1988.
[33]
T. G. Bolwig, M. M. Hertz, and O. B. Paulson, “The permeability of the blood brain barrier during electrically induced seizures in man,” European Journal of Clinical Investigation, vol. 7, no. 2, pp. 87–93, 1977.
[34]
P. L. Agulnik, A. Dimascio, and P. Moore, “Acute brain syndrome associated with lithium therapy,” American Journal of Psychiatry, vol. 129, no. 5, pp. 621–623, 1972.
[35]
H. A. Sackeim, E. M. Dillingham, J. Prudic et al., “Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects,” Archives of General Psychiatry, vol. 66, no. 7, pp. 729–737, 2009.
[36]
American Psychiatric Association, The Practice of ECT: Recommendations for Treatment, Training and Privileging, A.P. Press, Washington, DC, USA, 2nd edition, 2001.
[37]
G. Mekler and B. Woggon, “A case of serotonin syndrome caused by venlafaxine and lithium,” Pharmacopsychiatry, vol. 30, no. 6, pp. 272–273, 1997.
[38]
J. H. Kanto, “Midazolam: the first water-soluble benzodiazepine pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia,” Pharmacotherapy, vol. 5, no. 3, pp. 138–155, 1985.
[39]
J. G. Reves, R. J. Fragen, H. R. Vinik, and D. J. Greenblatt, “Midazolam: pharmacology and uses,” Anesthesiology, vol. 62, no. 3, pp. 310–324, 1985.
[40]
E. H. Liston and D. E. Sones, “Postictal hyperactive delirium in ECT: management with midazolam,” Convulsive Therapy, vol. 6, no. 1, pp. 19–25, 1990.
[41]
C. E. Mancuso, M. G. Tanzi, and M. Gabay, “Paradoxical reactions to benzodiazepines: literature review and treatment options,” Pharmacotherapy, vol. 24, no. 9, pp. 1177–1185, 2004.
[42]
A. Strahan, J. Rosenthal, M. Kaswan, and A. Winston, “Three case reports of acute paroxysmal excitement associated with alprazolam treatment,” American Journal of Psychiatry, vol. 142, no. 7, pp. 859–861, 1985.
[43]
R. L. Binder, “Three case reports of behavioral disinhibition with clonazepam,” General Hospital Psychiatry, vol. 9, no. 2, pp. 151–153, 1987.
[44]
B. L. Lobo and L. J. Miwa, “Midazolam disinhibition reaction,” Drug Intelligence and Clinical Pharmacy, vol. 22, no. 9, p. 725, 1988.
[45]
A. A. Weinbroum, O. Szold, D. Ogorek, and R. Flaishon, “The midazolam-induced paradox phenomenon is reversible by flumazenil. Epidemiology, patient characteristics and review of the literature,” European Journal of Anaesthesiology, vol. 18, no. 12, pp. 789–797, 2001.
